AB076. High expression of FTL protein in prostate cancer and its clinical significance

Background To study the differential expression of FTL in prostate cancer and benign prostatic hyperplasia (BPH) and its clinical significance Methods Thirty cases of prostate cancer and 30 cases of BPH were selected according to the random number table method, and performed immunohistochemistry experiments; 4 cases of prostate cancer and 4 cases of BPH were collected, and performed protein blotting experiments. Results High expression rate of FTL protein in prostate cancer and BPH were 63.3% and 20%, respectively. The difference has statistically significant (P<0.05). The FTL protein was no significant difference in the groups of age, PSA, prostate volume, Gleason score, clinical stage and lymph node metastasis (P>0.05). The expression level of FTL protein has statistically significant in the group of distant metastases (P<0.05). The expression level of FTL protein in prostate cancer and BPH were (1.52±0.27) and (0.41±0.21), respectively, and it has statistically significant (P<0.05). Conclusions FTL protein is highly expressed in prostate cancer, and it can be used as a new diagnostic tool for prostate cancer. FTL protein plays an important role in the development of prostate cancer.